CF:DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol BMBIF.

This company has cross-listed shares that trade in the U.S. as the symbol BMBIF.

1.80 CAD
As of 09/26/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Communication Services
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  01/01/1900
Stock exchange:    Canadian Securities Excha
Exchange country:   Canada
Market cap:   14,793,000 CAD
Current dividend yield:   0.00%
Sedol:      

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy